February 2026 · 10 min read · Reviewed by Decima Medical Team
In 2010, Dr. Mari Dezawa at Tohoku University in Japan published a paper that should have changed regenerative medicine. She had discovered a population of stress-resistant pluripotent stem cells within the mesenchymal stem cell fraction — cells that could survive extreme cellular stress, home to damaged tissue throughout the body, and differentiate into the specific cell types needed at the site of injury.
She called them MUSE cells — Multilineage-Stressing Undifferentiated Stem Cells. They are, to date, the only pluripotent stem cell type demonstrated to be non-tumorigenic in clinical conditions. Every other pluripotent stem cell type carries risk of teratoma formation. MUSE cells do not. This single property makes them clinically unique.
Standard MSCs (mesenchymal stem cells) work primarily through paracrine signaling — they secrete anti-inflammatory and growth factors that support healing in surrounding tissue. They are valuable, well-studied, and safe. But they are local in their action: injected into a knee, they work in the knee.
MUSE cells are different. When administered intravenously, they actively home to damaged tissue throughout the body by sensing stress signals — sphingosine-1-phosphate (S1P), a lipid messenger released by damaged cells. They migrate to sites of injury or disease, engraft, and differentiate into the cell type appropriate to that tissue. A single IV infusion can target multiple organ systems simultaneously.
MUSE cells have been studied in Phase 2 trials for ALS, stroke, diabetic neuropathy, and acute myocardial infarction. The stroke trial (TRY-1) showed statistically significant improvement in neurological function at 12 weeks. The ALS trial showed slowing of disease progression in a subset of patients. These are Phase 2 results — promising, not definitive. But they represent the most rigorous clinical evidence available for any stem cell type in systemic disease.
This article is for educational purposes only and does not constitute medical advice. Stem cell therapies are investigational and not FDA-approved to treat, cure, or prevent any specific disease or condition. Individual results vary. Consult your physician.